Literature DB >> 15102541

Genetic variability in CYP3A5 and its possible consequences.

Hong-Guang Xie1, Alastair J J Wood, Richard B Kim, C Michael Stein, Grant R Wilkinson.   

Abstract

The cytochrome P450 3A (CYP3A) subfamily members are the most abundant and important drug-metabolizing enzymes in humans, and wide interindividual variability in CYP3A expression and function is present. CYP3A4 alone cannot fully explain the observed constitutive variability because its genetic variants are relatively uncommon and have limited functional significance, whereas CYP3A5 expression in humans is highly variable and may be contributory. However, it is difficult to delineate the relative contribution of CYP3A4 and CYP3A5, and to differentiate their effects on drug metabolism as their protein structure, function and substrates are so similar. By contrast, molecular biology methods provide the ability to identify CYP3A4 and CYP3A5 genotypes with certainty. This review collates currently available data on CYP3A5 polymorphisms, provides information on the population frequency of each genetic variant in major ethnic groups, and describes in vitro and in vivo studies that have attempted to identify genotype-phenotype associations.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102541     DOI: 10.1517/phgs.5.3.243.29833

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN: 1462-2416            Impact factor:   2.533


  63 in total

1.  A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Authors:  Karthik Venkatakrishnan; Michael D Pickard; Lisa L von Moltke
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

2.  Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.

Authors:  Jane R Kenny; Sophie Mukadam; Chenghong Zhang; Suzanne Tay; Carol Collins; Aleksandra Galetin; S Cyrus Khojasteh
Journal:  Pharm Res       Date:  2012-03-14       Impact factor: 4.200

3.  Impact of CYP3A5 polymorphism on trough concentrations and outcomes of tacrolimus minimization during the early period after kidney transplantation.

Authors:  Khemjira Yaowakulpatana; Somratai Vadcharavivad; Atiporn Ingsathit; Nutthada Areepium; Surasak Kantachuvesiri; Bunyong Phakdeekitcharoen; Chonlaphat Sukasem; Supasil Sra-Ium; Vasant Sumethkul; Chagriya Kitiyakara
Journal:  Eur J Clin Pharmacol       Date:  2015-12-04       Impact factor: 2.953

4.  Relationships of related genetic polymorphisms and individualized medication of tacrolimus in patients with renal transplantation.

Authors:  Lin Zhu; Jing Zhang; Hongtao Song; Qinghua Wang; Jianming Tan; Weizhen Wu; Meiqin Lin
Journal:  Int J Clin Exp Med       Date:  2015-10-15

5.  Reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition.

Authors:  Su-Jun Lee; William J Jusko; Christine G Salaita; Karim A Calis; Michael W Jann; Vicky E Spratlin; Joyce A Goldstein; Yuen Yi Hon
Journal:  J Clin Pharmacol       Date:  2006-05       Impact factor: 3.126

6.  The predictive value of ABCB1, ABCG2, CYP3A4/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions.

Authors:  C Rafaniello; M Sessa; F F Bernardi; M Pozzi; S Cheli; D Cattaneo; S Baldelli; M Molteni; R Bernardini; F Rossi; E Clementi; C Bravaccio; S Radice; A Capuano
Journal:  Pharmacogenomics J       Date:  2017-07-18       Impact factor: 3.550

Review 7.  Significance of the minor cytochrome P450 3A isoforms.

Authors:  Ann K Daly
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  The limited impact of CYP3A5 genotype for the pharmacokinetics of CYP3A substrates.

Authors:  Oliver Burk; Matthias Schwab
Journal:  Eur J Clin Pharmacol       Date:  2007-12       Impact factor: 2.953

9.  Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

Authors:  Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2008-11-17       Impact factor: 4.335

10.  HLA-B*51:01 is strongly associated with clindamycin-related cutaneous adverse drug reactions.

Authors:  Y Yang; S Chen; F Yang; L Zhang; G Alterovitz; H Zhu; J Xuan; X Yang; H Luo; J Mu; L He; X Luo; Q Xing
Journal:  Pharmacogenomics J       Date:  2016-08-16       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.